Exploring Upadacitinib's Impact on Giant Cell Arthritis Treatment

This chapter reviews a pivotal study from ACR 2024 on the use of upadacitinib in managing giant cell arthritis, comparing various steroid tapering regimens. It highlights sustained remission rates at week 52 and discusses the implications for current treatments like tocilizumab and the challenges of incorporating upadacitinib into clinical practice.

Play episode from 24:46

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app